Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22615461 | 1.00 | CASP1 (0.34) | CASP1EPHX1ALDH1A1NPSR1LMNA | |
| SCHEMBL22615669 | 1.00 | CASP1 (0.34) | CASP1EPHX1ALDH1A1NPSR1LMNA | |
| SCHEMBL22615974 | 1.00 | CASP1 (0.34) | CASP1EPHX1ALDH1A1NPSR1LMNA | |
| SCHEMBL22616007 | 0.82 | CASP1 (0.32) | CASP1 | |
| SCHEMBL21273766 | 0.78 | ALDH1A1 (0.40) | EPHX1ALDH1A1NPSR1LMNACYP1A2 | |
| SCHEMBL22615480 | 0.77 | CYP2C19 (0.40) | EPHX1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22615802 | 0.77 | CYP2C19 (0.40) | EPHX1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22615603 | 0.77 | CYP2C19 (0.40) | EPHX1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3858382 | 0.75 | ALDH1A1 (0.33) | EPHX1ALDH1A1NPSR1SMN1; SMN2MEN1 | |
| SCHEMBL22615782 | 0.73 | NAAA (0.34) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | claimed |
| EP-3962602-B1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2025-06-25 | — | — | EP | claimed |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2022-08-25 | — | — | US | claimed |
| EP-3962602-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | claimed |
| EP-3962888-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | claimed |
| CN-113825740-A | Itaconic acid derivatives and their use in the treatment of inflammatory diseases or diseases associated with adverse immune reactions | 西特瑞治疗有限公司 | 2021-12-21 | — | — | CN | claimed |
| WO-2020222010-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | claimed |
| WO-2020222011-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | claimed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-3962602-B1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2022-08-25 | — | — | US | disclosed |
| EP-3962602-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962888-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| CN-113825740-A | Itaconic acid derivatives and their use in the treatment of inflammatory diseases or diseases associated with adverse immune reactions | 西特瑞治疗有限公司 | 2021-12-21 | — | — | CN | disclosed |
| WO-2020222010-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020222011-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | IL1R1, IL1B, IL1A | CASP1 63/4885EPHX1 881/4885ALDH1A1 9/4885 |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | IL1R1, IL1B, IL1A | CASP1 63/4885EPHX1 881/4885ALDH1A1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.